Have u read 2017 annual report? You’ll get some idea about the financial implications as well as nature of partnership with JCR. Being MSB shareholders i think we have to focus on what sort of strategy JCR has in place to ramp up sales for TEMCELL and its execution risk. Regarding hard nose negotiators its not MSB who did agreement with JCR. It was done between osiris and JCR, however i’m not implying that MSB management would have done better - i just don’t know. Data generated by JCR from the TEMCELL also can be presented to FDA-claimed by silvu itsecu). Thats one of the reason why i’m so upbeat about agvhd treatment approval in US. It will provide further reputational boost to MSB technology .
Mesoblast has turned a corner, page-835
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.020(1.78%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.13 | $1.09 | $4.556M | 4.141M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9590 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 3132 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |